New Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs, and Program Leadership Phio ...

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the best money-making stocks to buy right now. On February 13, Morgan Stanley trimmed the price target on Alnylam Pharmaceuticals, Inc.

Korsana’s lead program uses a next-generation shuttling technology to improve delivery into the brain and lower the incidence of amyloid-related imaging abnormalities.

Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressed—and there’s more to come in ...

TheFly reported on February 6 that Morgan Stanley lowered its price target for ARWR to $78 from $81 and kept an Equal Weight rating.

University of Queensland research has revealed that double-stranded RNA-based biopesticides (dsRNA) sprayed on plant leaves ...

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology ...

Management will participate in a fireside chat on Tuesday, March 3, 2026, at 11:50 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, ...

Alnylam took the wraps off its fourth-quarter and full-year 2025 results before market open. These revealed that the ...

Phio Pharma stock fell after a recent rally, despite strong Phase 1b trial results showing an 85% response rate. Analysts maintain Buy ratings as shares trade near 52-week lows.